Financial Gravity Asset Management’s CRISPR Therapeutics CRSP Stock Holding History

Financial Gravity Asset Management’s Portfolio CRSP Stock Details CRSP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	–	Sell	-5	Closed	-$312	–	1646
2024 Q1	$312	Sell	5 -151	-97%	-$10.8K	﹤0.01%	1521
2023 Q4	$6.07K	Hold	156	–	–	﹤0.01%	853
2023 Q3	$6.07K	Buy	156 +100	+179%	+$5.17K	﹤0.01%	624
2023 Q2	$387	Buy	+56	New	+$3.18K	﹤0.01%	1041
2023 Q1	–	Sell	-41	Closed	-$394	–	1251
2022 Q4	$394	Sell	41 -1,064	-96%	-$56.4K	﹤0.01%	835
2022 Q3	$3.51K	Buy	+1,105	New	+$80.1K	0.12%	185
2022 Q2	–	Sell	-63	Closed	-$4	–	760
2022 Q1	$4	Sell	63 -13	-17%	-$816	﹤0.01%	815
2021 Q4	$6	Buy	+76	New	+$6.64K	﹤0.01%	886
2021 Q3	–	Hold	0	–	–	–	322

Other funds holding CRSP

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

NMC

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

Financial Gravity Asset Management's CRSP Position: Q2 2024 in Review

Financial Gravity Asset Management sold out of CRISPR Therapeutics (CRSP) in Q2 2024, closing a stake of 5 shares — an estimated $312 sold.

Financial Gravity Asset Management first reported a position in CRSP in Q4 2021 and held it in 8 quarters. The position peaked at $6.07K in Q4 2023. 449 funds tracked by Wall St. Rank hold CRSP as of Q2 2024.

Financial Gravity Asset Management reported no remaining CRISPR Therapeutics position as of Q2 2024 after selling out during the quarter.
Financial Gravity Asset Management sold 5 CRISPR Therapeutics shares in Q2 2024, an estimated $312.
Financial Gravity Asset Management first reported a position in CRISPR Therapeutics in Q4 2021 and held it in 8 quarters.
Financial Gravity Asset Management's CRISPR Therapeutics position peaked at $6.07K in Q4 2023.
449 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q2 2024.

Based on Financial Gravity Asset Management's 13F filing for Q2 2024, filed 6 Aug 2024.